Sign up Australia
Proactive Investors - Run By Investors For Investors

Pharmaxis making strong progress with significant value inflection points ahead

Gary Phillips, chief executive of Pharmaxis Ltd (ASX:PXS) tells Proactive they're continuing to make good progress with their drug development programmes.

After receiving $42 million in milestone payments from Boehringer Ingelheim, the company expects more results later in 2018 which will impact the risk-adjusted valuation of the deal.

Phillips says the NASH study is due to read out in the September quarter and the diabetic retinopathy study in the December quarter this year.

He adds that both studies will provide the first clinical proof of concept in humans and, if positive, would represent a huge step forward in their progress.

The second key event for Pharmaxis will be the mid‐year read out from the phase 1 studies that are underway on their two lead candidates from the anti fibrotic LOXL2 program.

 
Meet Tower Resources PLC, Arc Minerals Limited, Carbon Tracker and Tekcapital PLC at our event, London , 31 May 2018. Register here »
View full PXS profile View Profile

Pharmaxis Ltd Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use